Since the failure of imatinib, sunitinib malate (Sutent), a multi-target TKI with powerful activity againstKIT and PDGFRA, as well as a number of other kinases, has demonstrated efficacy as a second-line therapy and is now approved globally for use in metastatic GIST in patients who are resistant or intolerant to imatinib based on the results of a double-blind, placebo-controlled phase III trial24. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.